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Diminished insulin sensitivity in the peripheral tissues and failure of pancreatic beta cells to secrete
insulin are known major determinants of type 2 diabetes mellitus. JTT-130, an intestine-speciﬁc
microsomal transfer protein inhibitor, has been shown to suppress high fat-induced obesity and
ameliorate impaired glucose tolerance while enhancing glucagon-like peptide-1 (GLP-1) secretion. We
investigated the effects of JTT-130 on glucose metabolism and elucidated the mechanism of action, direct
effects on insulin sensitivity and glucose-stimulated insulin secretion in a high fat diet-induced obesity
rat model. Male Sprague Dawley rats fed a high-fat diet were treated with a single administration of JTT-
130. Glucose tolerance, hyperglycemic clamp and hyperinsulinemic-euglycemic testing were performed
to assess effects on insulin sensitivity and glucose-stimulated insulin secretion, respectively. Plasma GLP-
1 and tissue triglyceride content were also determined under the same conditions. A single adminis-
tration of JTT-130 suppressed plasma glucose elevations after oral glucose loading and increased the
disposition index while elevating GLP-1. JTT-130 also enhanced glucose-stimulated insulin secretion in
hyperglycemic clamp tests, whereas increased insulin sensitivity was observed in hyperinsulinemic-
euglycemic clamp tests. Single-dose administration of JTT-130 decreased lipid content in the liver and
skeletal muscle. JTT-130 demonstrated acute and direct hypoglycemic effects by enhancing insulin
secretion and/or insulin sensitivity.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus is widely prevalent and has become
one of the major health problems worldwide. The disease is a
complex metabolic disorder and numerous organs are known to
take part in the disease state (1). Therefore, pharmacological
therapies that target several organs have been developed to
decrease blood glucose level, such as sulfonylureas (targeting
pancreatic beta cells), metformin (targeting the liver) and thiazo-
lidine dions (targeting insulin sensitive tissues). glucagon-like
peptide-1 (GLP-1)-related therapies (targeting pancreatic beta and
alpha cells) and sodium glucose cotransporter 2 inhibitorsacological Society.
. Production and hosting by Else(targeting kidneys) are recent therapeutic options (2e4). However,
impaired insulin secretion and insulin activity are still important
determinants for the development of type 2 diabetes.
Microsomal triglyceride transfer protein (MTP) is known to take
part in the mobilization and secretion of triglyceride (TG)-rich li-
poproteins from enterocytes and hepatocytes (5). JTT-130, a novel
intestine-speciﬁc inhibitor of MTP suppresses the absorption of
dietary fat and cholesterol in the intestine and decreases plasma TG
and total cholesterol (TC) without resulting in accumulation of
hepatic TG (6,7). JTT-130 suppresses high fat diet-induced obesity
and improves glucose and lipid metabolic abnormalities while
elevating plasma GLP-1 in Sprague Dawley (SD) rats and Zucker
diabetic fatty (ZDF) rats (8e11).
JTT-130 is expected to have another mechanism of action for
improving glycemic control other than anti-obesity effects; how-
ever, evaluating the direct effects of JTT-130 on glycemic control has
been difﬁcult, since repeated administration of JTT-130 decreasesvier B.V. This is an open access article under the CC BY-NC-ND license (http://
S. Sakata et al. / Journal of Pharmacological Sciences 127 (2015) 103e108104food intake and suppresses obesity. In the present study, we
investigated the effect of a single administration of JTT-130 on
glucose tolerance, glucose-stimulated insulin secretion and insulin
sensitivity by eliminating the anti-obesity effects of the drug in
high fat-induced obese SD rats.




ylmalonate, and pioglitazone were synthesized by Japan Tobacco
Inc. (Osaka, Japan). All other reagents used in this study were ob-
tained commercially.
2.2. Animals and diets
Male SD rats (5 weeks of age) were obtained from Charles River
Laboratories (Yokohama, Japan), individually housed in an envi-
ronment with controlled temperature, humidity, and lighting
(23± 3 C, 55± 15%, and a 12-h light/dark cycle with lights on at
8:00 AM), and were provided a high-fat diet (35%; Oriental Yeast,
Osaka, Japan) and water ad libitum after acquisition.
Four separate studies were conducted under the same condi-
tions as described below. SD rats were divided into 2 groups, a
control group and a JTT-130 treatment group, according to body
weight and food consumption during several days prior to the
studies. After subjecting the rats to fasting for 24 h from 10:00 AM,
rats were treated with a single administration of vehicle solution
(0.5% methylcellulose, 5 mL/kg) or JTT-130 (10 mg/kg) at 10:00 AM,
and were fed a high-fat diet for 6 to 8 h. Rats were then fasted
overnight and in the next morning oral glucose tolerance tests,
hyperglycemic clamp tests or hyperinsulinemic-euglycemic clamp
tests were performed in Study 1, 2 and 3. Tissue lipid content was
measured under the same conditions in Study 4. All procedures
were conducted according to the Japan Tobacco Animal Care
Committee's guidelines.
2.3. Intraperitoneal glucose tolerance test (ipGTT) (Study 1)
ipGTTwas performed to the rats (8 weeks of age) after overnight
fasting. Glucose solution (1 g/kg) was intraperitoneally adminis-
tered to rats and blood samples were collected from the tail vein
prior to and at 7, 30, 60 and 120 min after glucose loading. Plasma
glucose levels were measured using commercial kits (Roche Di-
agnostics, Basel, Switzerland) and an automatic analyzer (Hita-
chi7170S, Tokyo, Japan). Plasma insulin level was measured with a
rat-insulin enzyme-linked immunosorbent assay (ELISA) kit (Mor-
inaga Institute of Biological Science, Yokohama, Japan). Plasma GLP-
1 levels were evaluated just prior to the ipGTT with a commercial
kit (Immuno-Biological Laboratories, Gunma, Japan). The disposi-
tion index (DI) was calculated as △I0e30 (change in insulin from
0 to 30 min)/△G0e30 (change in glucose from 0 to 30 min) x (1/
fasting glucose x fasting insulin), and was used as an index for in-
sulin secretion.
2.4. Hyperglycemic clamp test (Study 2)
Hyperglycemic clamp tests were performed to the rats (10 weeks
of age) after overnight fasting in a separate study. Blood was
collected via a carotid artery cannula at30,20,10, and 0 min to
measure blood glucose levels using a compact glucose analyzer
(Antsense III). After blood sampling at zero minutes, a 25% glucose
solution (equivalent to 300 mg/kg) was infused via a jugular veincannula over one minute using a syringe pump. Blood glucose level
was subsequently monitored at two and ﬁve minutes after infusion
and every ﬁve minutes thereafter for up to 90 minutes, and main-
tained at around 350 mg/dL by adjusting the infusion rate of the 25%
glucose solution. Approximately 100 mL of blood was collected in a
heparinized tube at30,20,10, 0, 2, 5, and 10minutes and every
10 minutes thereafter for up to 90 min to measure plasma insulin
concentrations. Blood was centrifuged (4 C, 10,000  g, ﬁve mi-
nutes) to obtain plasma. Plasma was stored at 20 C until mea-
surement. Insulin areas above base line from 0e5 min after glucose
infusion were calculated as the ﬁrst-phase insulin secretion. More-
over, the insulin areas above base line from 10e90min after glucose
infusion were calculated as the second-phase insulin secretion.
2.5. Hyperinsulinemic-euglycemic clamp test (Study 3)
Hyperinsulinemic-euglycemic clamp tests were performed to
the rats (7 weeks of age) after overnight fasting in a separate study.
A bolus dose of [3-3H] glucose solution (740 kBq/head) was injected
via a jugular vein cannula, followed by continuous infusion at a rate
of 7.4 kBq/min. At 110, 115 and 120 min after the start of the [3-3H]
glucose infusion, blood samples (approximately 200 mL) were
collected into heparinized tubes via a carotid artery cannula to
determine parameters in the basal period. After blood sampling, a
bolus dose (0.5 U/kg) of insulin was injected via the jugular vein
cannula, followed by continuous infusion of [3-3H] glucose and
insulin at the rates of 7.4 kBq/min and 7 mU/kg/min, respectively.
Thereafter, blood samples were collected every ﬁve minutes via the
carotid artery cannula for blood glucose monitoring using a
compact glucose analyzer, and the infusion rate of 25% glucose
solution via the jugular vein cannula was adjusted to maintain
blood glucose levels at 110± 10 mg/dL. Steady-state was deﬁned as
the condition in which blood glucose levels were maintained at
110± 10 mg/dL without any alteration in glucose infusion rate for
30 min (6 points of continuous glucose monitoring). At the latter 3
points of steady-state, blood samples (approximately 200 mL) were
collected into heparinized tubes to determine parameters in the
clamp period. Blood samples were immediately centrifuged at
10,000  g for ﬁve minutes at 4 C to obtain plasma. Plasma was
stored at 20 C until the measurement of plasma parameters. The
rate of glucose disappearance (Rd) and hepatic glucose production
(HGP) were calculated using Steele’s equation from tracer data as
previously described (12). In the basal state, HGP was calculated as
Rd. HGP during the clamp study was calculated as the difference
between Rd and the infusion rate of exogenous glucose.
2.6. Measurement of tissue lipid content (Study 4)
Lipid content in tissues, such as the liver and skeletal muscle of
the rats (7 weeks of age), was measured after overnight fasting in a
separate study. After adding 1.5 mL of methanol, liver slices were
sufﬁciently homogenized using one zirconia ball (YTZ® Ball, Nik-
kato Corp.) and a mixer mill (MM300, Retsch Co., Ltd.). Four hun-
dred mL of chloroform was added to 400 mL of homogenates and
mixed. Mixtures were centrifuged at 10,000  g for 5 min and
supernatants were collected. Supernatants were evaporated under
a nitrogen gas ﬂow and residues were dissolved in 500 mL of 2-
propanol. TG and free fatty acid (FFA) concentrations in the 2-
propanol solution were measured by an enzymatic colorimetric
method using an automatic biochemical analyzer or microplate
reader and hepatic TG and FFA content were calculated.
After adding 1 mL of methanol, skeletal muscle slices were
sufﬁciently homogenized using one zirconia ball (YTZ® Ball, Nik-
kato Corp.) and a mixer mill (MM300, Retsch Co., Ltd.). Eight
hundred mL of chloroformwas added to 800 mL of homogenates and
Fig. 2. Changes in plasma glucose (A) and insulin (B) levels in the control group and
JTT-130 treatment group in ipGTT. Data represent mean values ± s.d. (n ¼ 6). *p < 0.05,
**p < 0.01; signiﬁcantly different from control group.
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supernatants were collected. Supernatants were evaporated under
a nitrogen gas ﬂow and residues were dissolved in 100 mL of 2-
propanol. TG concentrations in the 2-propanol solutions were
measured by an enzymatic colorimetric method using an automatic
biochemical analyzer or microplate reader and TG content in
skeletal muscle was calculated.
2.7. Statistical analysis
Data were expressed as mean values± s.d or þ s.d. Student's t-
tests or Aspin-Welch tests were used to determine statistical sig-
niﬁcance. P < 0.05 was considered statistically signiﬁcant. In hy-
perglycemic clamp test (study 2), statistical analysis was performed
in the ﬁrst-phase insulin secretion and the second-phase insulin
secretion. In hyperinsulinemic-euglycemic clamp test (study 3), the
analysis was performed in each value of steady-state.
3. Results
3.1. Intraperitoneal glucose tolerance test
As previously reported (9), a single administration of JTT-130
increased plasma GLP-1 levels in this study (Fig. 1). There were
no signiﬁcant effects on body weights prior to testing (Control;
298.0± 18.9 g, JTT-130; 292.2± 8.6 g, p¼ 0.51) and changes in body
weights (Control; 4.9± 4.3 g, JTT-130; 8.0± 4.3 g, p ¼ 0.24)
during the experiment, thus an evaluation of the effects of JTT-130
on glucosemetabolismwithout inﬂuencing anti-obesity effects was
considered possible. Changes in plasma glucose and insulin levels
in ipGTT are shown in Fig. 2. In ipGTT, plasma glucose levels were
signiﬁcantly lower in the JTT-130 treatment group than in the
control group (Fig. 2(A)), showing that JTT-130 improved glucose
tolerance. Plasma insulin levels in the JTT-130 treatment group did
not signiﬁcantly increase compared with the control group; how-
ever, DI tended to increase (Control; 3.05± 0.40 (105$(mg/dL)-2),
JTT-130; 7.74± 2.25 (105$(mg/dL)2, p ¼ 0.17).
3.2. Hyperglycemic clamp test
Since hyperglycemia induced by glucose loading in ipGTT was
transient, detecting the effects of JTT-130 on insulin secretion may
be insufﬁcient. Thus, we examined the effects of JTT-130 onFig. 1. Changes in plasma GLP-1 levels in the control group and JTT-130 treatment
group in ipGTT. Data represent mean values þ s.d. (n ¼ 6). **p < 0.01; signiﬁcantly
different from control group.glucose-stimulated insulin secretion under sustained hyperglyce-
mic conditions using hyperglycemic clamp techniques in the next
study. There were no signiﬁcant effects on body weights prior to
testing (Control; 428.2± 47.3 g, JTT-130; 431.5± 20.0 g, p ¼ 0.87),
and changes in body weights (Control; 2.3± 5.5 g, JTT-
130; 1.8± 2.9 g, p ¼ 0.85) and food consumption (Control;
14.6± 1.3 g, JTT-130; 13.5± 2.2 g, p ¼ 0.28) during the experiment.
Prior to the initiation of glucose infusion, there were no signiﬁ-
cant changes in plasma insulin levels between both groups, sug-
gesting that JTT-130 did not affect insulin secretion in the fasting
state. After the initiation of glucose infusion, plasma glucose
levels were maintained at approximately 350 mg/dL in both
groups from 50 min after glucose infusion until the end of the
study. An increase in plasma insulin levels corresponding to the
increase in blood glucose was observed in both groups and was
almost similar between the two groups at two minutes after the
start of glucose infusion (ﬁrst-phase insulin secretion). In contrast,
the mean insulin level from 10 to 90 min (second-phase insulin
secretion) tended to increase in the JTT-130 group compared with
the control group (p ¼ 0.068), showing that a single administra-
tion of JTT-130 tended to increase glucose-stimulated insulin
secretion (Fig. 3).
Fig. 3. Changes in blood glucose (A) and plasma insulin (B) levels in the control group
and JTT-130 treatment group in hyperglycemic clamp tests. Data represent mean
values ± s.d. (n ¼ 7). Insulin areas above base line from 0e5 min are considered as ﬁrst-
phase insulin secretion, and the areas above base line from 10e90 min are considered
as second-phase insulin secretion.
Table 1
Blood glucose and plasma insulin levels, GIR, Rd and HGP in the hyperinsulinemic-
euglycemic clamp study.
Control JTT-130
Glucose (mg/dL) Basal 135 ± 4 127± 5
Clamp 112± 2 113± 2
Insulin (ng/mL) Basal 4.3± 0.4 4.3± 0.4
Clamp 12.7± 1.6 10.4± 1.5
GIR (mg/kg/min) 5.4± 2.5 15.2± 0.5**
Rd (mg/kg/min) Basal 8.0± 0.4 7.6± 0.4
Clamp 11.8± 0.5 14.1± 0.7*
HGP (mg/kg/min) Basal 8.0± 0.4 7.6± 0.4
Clamp 6.4± 2.3 1.1± 0.8*
Data representmean values± s.d. (n¼ 6). *p < 0.05, **p < 0.01; signiﬁcantly different
from control group. Each parameter was measured or calculated during the last
15 min of the clamp.
Fig. 4. Changes in blood glucose levels (A) and glucose infusion rate (B) in the control
group and JTT-130 treatment group in hyperinsulinemic-euglycemic clamp tests. Data
represent mean values ± s.d. (n ¼ 5e6).
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To elucidate the mechanism of action of JTT-130 responsible for
ameliorating impaired glucose tolerance without affecting plasma
insulin levels, a hyperinsulinemic-euglycemic clamp test to assess
the effects of JTT-130 on insulin sensitivity was performed. There
were no signiﬁcant effects on body weights prior to testing (Con-
trol; 274.9± 14.2 g, JTT-130; 277.0± 13.7 g, p ¼ 0.80), and changes
in bodyweights (Control;1.2± 4.3 g, JTT-130; 1.4± 3.8 g, p¼ 0.33)
and food consumption (Control; 13.8± 3.0 g, JTT-130; 11.7± 1.8 g,
p ¼ 0.20) during the experiment. Compared with the basal period,
plasma insulin levels were maintained at higher levels during the
clamp period and there were no signiﬁcant differences between
both groups (Table 1). The plasma glucose levels in both groups
were maintained at 110± 10 mg/dL at 140 min and after (Fig. 4A).
Glucose infusion rates in the JTT-130 group were signiﬁcantlyhigher than the control group (Table 1 and Fig. 4B). A tracer study
showed that Rd was signiﬁcantly higher and HGP was signiﬁcantly
lower in the JTT-130 treatment group compared with the control
group, indicating that a single administration of JTT-130 improved
insulin sensitivity, both in the liver and peripheral tissues (Table 1).
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Since JTT-130, an intestine-speciﬁc MTP inhibitor, was consid-
ered to inhibit lipid absorption in the small intestine, JTT-130 was
expected to affect tissue lipid content that has been reported to be
associatedwith insulin sensitivity in tissues. Thus, the effects of JTT-
130 on lipid content (TG and FFA) in the liver and skeletal muscle
were assessed. There were no signiﬁcant effects on body weights
prior to testing (Control; 288.0± 16.6 g, JTT-130; 286.5± 18.4 g,
p ¼ 0.86), and changes in body weights (Control; 6.7± 3.6 g, JTT-
130; 6.9± 6.5 g, p ¼ 0.95) and food consumption (Control;
14.8± 2.0 g, JTT-130; 13.4± 3.1 g, p ¼ 0.30) during the experiment.
TG and FFA content in the liver and TG content in the skeletal
muscle were lower in the JTT-130 treatment group than in the
control group. In particular, the effects on FFA content in the liver
and TG content in the soleus muscle were signiﬁcant (Fig. 5).
4. Discussion
To date, several oral diabetic agents, such as pioglitazone, which
enhances insulin sensitivity of insulin target organs, and GLP-1
analogs or dipeptidyl peptidase-4 inhibitors, which enhance
glucose-stimulated insulin secretion from the pancreas, have been
developed for type 2 diabetes management (13e15). However, to
our knowledge, there are no reported agents that directly affect
insulin sensitivity and glucose-stimulated insulin secretion.
In the present study, we intended to evaluate the effects of a
single administration of JTT-130 on glucose metabolism by elimi-
nating its anti-obesity effects. As shown in the previous report, theFig. 5. Effect on lipid content in the liver (A), (B) and skeletal muscle (C), (D) in the control g
**p < 0.01; signiﬁcantly different from control group.signiﬁcant inﬂuence was observed on food intake for 24 h after a
single administration of JTT-130 (8). However, a single adminis-
tration of JTT-130 (and subsequent food intake for 6 to 8 h) had no
signiﬁcant effects on food intake and body weight, indicating the
ability to assess the effects of JTT-130 on glucose metabolism in the
present series of studies. In ipGTT after fasting overnight, JTT-130
improved glucose tolerance, and increased DI while elevating
GLP-1 levels. DI quantiﬁes the nature of the interactions between
pancreatic insulin secretion and insulin sensitivity, and the index is
considered to be predictive of development of type 2 diabetes
(16,17). Indeed, JTT-130 tended to enhance glucose-stimulated in-
sulin secretion under sustained hyperglycemic conditions; how-
ever, another mechanism of action of JTT-130 for ameliorating
glucose tolerance was considered. JTT-130 was found to improve
insulin sensitivity in the liver and peripheral tissues in
hyperinsulinemic-euglycemic tests. Thus, one possible reason as to
why the effects on insulin secretion were not signiﬁcantly detected
in ipGTT was the dual effect of JTT-130 on enhanced glucose-
stimulated insulin secretion (elevated insulin secretion) and
enhanced insulin sensitivity (suppressed insulin secretion).
Increased tissue lipid content in the liver and skeletal muscle
(ectopic fat deposition) has been widely reported as reducing in-
sulin sensitivity and being associated with insulin resistance in
animal models and humans (18e21). We found that JTT-130
decreased lipid content in the liver and skeletal muscle, suggest-
ing that these effects may be the possible mechanism for the effects
of JTT-130 on insulin sensitivity. There are some reports in which
the insulin resistance can be induced by relatively short-time
infusion of lipids in rodents and human (22,23), and it isroup and JTT-130 treatment group. Data represent mean values þ s.d. (n ¼ 8). *p < 0.05,
S. Sakata et al. / Journal of Pharmacological Sciences 127 (2015) 103e108108considered that JTT-130 improved insulin resistance in tissue via
decreased exposure of fat to the tissues by blockade of fat
absorption.
It is noteworthy that these effects of JTT-130 (enhanced glucose-
stimulated insulin secretion and insulin sensitivity) can be attrib-
uted to one mechanism of action of JTT-130, the blockade of fat
absorption in the small intestine. Blockade of fat absorption by JTT-
130 causes increases in fatty acid content in the lumen of the small
intestine and leads to the elevation of the plasma GLP-1 levels.
Suppressed fat absorption in the intestine may limit the supply of
fat in circulation and subsequently in tissues, such as the liver and
skeletal muscle.
In summary, these ﬁndings demonstrate that a single adminis-
tration of JTT-130, an intestine-speciﬁc MTP inhibitor, enhanced
glucose-stimulated insulin secretion and insulin sensitivity in high
fat-induced obese SD rats. These results suggest that pharmaco-
logical inhibition of fat absorption in the small intestine may be a
useful therapeutic target for the treatment of type 2 diabetes
mellitus.
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